Dose Cancer Research Results

Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
257- AL,  Cisplatin,    Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors
- in-vitro, NSCLC, A549
ROS↑, HIF-1↓, E-cadherin↑, N-cadherin↓, antiOx↓, Dose↝,
5361- almon,    Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
- Trial, NSCLC, NA
EGFR↓, OS↑, Dose↝,
5360- almon,  BEV,    Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series
- Case Report, NSCLC, NA
BBB↑, Dose↝, eff↓, OS↑,
5716- BF,    Pilot Study of Huachansu in Patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, or Pancreatic Cancer
- Trial, NSCLC, NA - Trial, PC, NA - Trial, HCC, NA
Dose↝, toxicity↓, other↓, QoL↑, OS?,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   ROS↑, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   N-cadherin↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   HIF-1↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 4,   eff↓, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  

Functional Outcomes ⓘ

OS?, 1,   OS↑, 2,   QoL↑, 1,   toxicity↓, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Dose, Dosage
2 almonertinib
1 Allicin (mainly Garlic)
1 Cisplatin
1 Bevacizumab (brand Avastin)
1 Bufalin/Huachansu
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page